Prostat Kanseri Gelişimi, Patofizyolojisi ve Moleküler Biyolojisi
Özet
Prostat kanseri (PK), dünya genelinde erkeklerde en sık görülen ve akciğer kanserinden sonra en çok ölüme neden olan ikinci malignitedir. Prostat spesifik antijen (PSA) testinin yaygınlaşmasıyla tanı oranı artmış, ancak bu durum klinik olarak önemsiz kanserlerin de fazladan tedavi edilmesine yol açmıştır. Bu sınırlılıkları aşmak adına hastalığın patofizyolojisi ve moleküler biyolojisini anlamaya yönelik araştırmalar yoğunlaşmıştır. Prostat tümörlerinin yaklaşık %75'i periferik zondan kaynaklanır ve vakaların %95'ini luminal hücre atipisi ile karakterize adenokarsinomlar oluşturur. Hastalığın gelişiminde, testosteronun dihidrotestosterona (DHT) dönüşmesi ve androjen reseptörlerinin (AR) uyarılması kritik bir rol oynamaktadır; düşük androjen seviyeleri ise androjenden bağımsız agresif tümör gelişimini tetikleyebilmektedir. Ayrıca, peptid büyüme faktörleri (IGF-1, EGF) ve PI3K-AKT-mTOR yolunun aktivasyonu, özellikle kastrasyon rezistan PK ilerlemesinde etkilidir. Tümör mikroçevresi ve apoptozis mekanizmasındaki bozulmalar, özellikle Bcl-2 aşırı ekspresyonu, kemoradyoterapi direncine yol açar. Genetik açıdan PK, kalıtsal ve sporadik formlara ayrılır. Sporadik formda C-myc, Bcl-2 onkogenleri ile PTEN ve p53 gibi tümör supresör genlerdeki mutasyonlar veya GSTP1'in hipermetilasyonu gibi epigenetik değişiklikler etkilidir. Ayrıca E-kadherin ve KAI1/CD82 ekspresyonunun azalması metastaz sürecini hızlandırır. Güncel araştırmalar, gereksiz tedavileri önleyecek ve hızlı ilerleyen vakalarda en etkili tedavi yöntemini belirleyecek moleküler belirteçler bulmayı amaçlamaktadır.
Prostate cancer (PC) is the second most common malignancy and the second leading cause of cancer-related death in men worldwide. Although the widespread use of the prostate-specific antigen (PSA) test has increased the detection rate, it has also led to overdiagnosis and overtreatment of clinically insignificant cancers, shifting research interest toward understanding the pathophysiology and molecular biology of the disease. Approximately 75% of prostate tumors originate from the peripheral zone, and 95% of cases are adenocarcinomas characterized by atypical luminal cells and loss of basal cells. Androgens play a crucial role in prostate development; testosteron is converted into dihydrotestosterone (DHT), which binds to androgen receptors (AR), whereas low androgen environments can exert selective pressure for aggressive, androgen-independent tumor growth. Additionally, peptide growth factors like IGF-1 and EGF facilitate AR-regulated proliferation, and the activation of the PI3K-AKT-mTOR pathway drives progression, particularly in castration-resistant PC. The tumor microenvironment promotes cancer stem cells, while defects in apoptosis, such as Bcl-2 overexpression, lead to chemo-radiotherapy resistance in aggressive types. Genetically, PC involves hereditary and sporadic pathways; the sporadic progression is driven by oncogenes like C-myc and Bcl-2, the fusion of TMPRSS2 with ERG/ETV1, and the inactivation of tumor suppressor genes such as PTEN, p53, and GSTP1 via hypermethylation. Furthermore, decreased expression of metastasis suppressors like E-cadherin and KAI1/CD82 correlates with advanced tumor stage, and current research aims to discover precise molecular biomarkers to differentiate indolent cases from aggressive ones to optimize therapeutic strategies.
Referanslar
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2019;69:7–34. Doi: 10.3322/caac.21551
Zorlu F, Zorlu R, Divrik RT, et al. Prostate cancer incidence in Turkey: an epidemiological study. Asian Pac J Cancer Prev. 2014;15:9125-9130. Doi: 10.7314/apjcp.2014.15.21.9125
Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Eng J Med. 1987;317:909-916. Doi: 10.1056/NEJM198710083171501
Merrill RM, Feuer EJ, Warren JL, et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol.1999;150(8):848-860.Doi:10.1093/oxfordjournals.aje.a010090
F Gentile, M Ferro, B Della Ventura, et al. Optimized Identification of High-Grade Prostate Cancer by Combining Different PSA Molecular Forms and PSA Density in a Deep Learning Model. Diagnostics. 2021;18;11(2):335. Doi:10.3390/diagnostics11020335
R Toivanen, MM Shen. Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development. 2017;144(8):13821398. Doi:10.1242/dev.148270
McNeal, J. E. . The zonal anatomy of the prostate. The Prostate. 1981;2(1):35–49. Doi: 10.1002/pros.2990020105
PA Humphrey. Histopathology of prostate cancer. Cold Spring Harb Perspect Med. 2017;7:a030411. doi: 10.1101/cshperspect.a030411
SH Lee, MM Shen. Cell types of origin for prostate cancer. Curr Opin Cell Biol. 2015;37:35-41. Doi: 10.1016/j.ceb.2015.10.002.
KB Blagoev, R Iordanov, M Zhou, et al. Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. Oncotarget. 2021:5;12(1):15-21. Doi:10.18632/oncotarget.27855.
ZA Wang, A Mitrofanova, SK Bergren, et al. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity Nat Cell Biol. 2013;15(3):274-283. Doi:10.1038/ncb2697.
PA Humphrey, H Moch, AL Cubilla, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70(1):106-119. Doi: 10.1016/j.eururo.2016.02.028.
JI Epstein, L Egevad, MB Amin, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 ;40(2):244-252. Doi: 10.1097/PAS.0000000000000530.
Packer JR, Maitland NJ. The molecular and cellular origin of human prostate cancer. Biochim Biophys Acta. 2016;1863:1238-1260.15.
S Shappell. G Thomas, R Roberts, et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004:15;64(6):2270-2305. Doi:10.1158/0008-5472.CAN-03-0946
Eminaga O, Hinkelammert R, Abbas M, et al. High-grade prostatic intraepithelial neoplasia (HGPIN) and topographical distribution in 1,374 prostatectomy specimens: existence of HGPIN near prostate cancer. Prostat. 2013;73:1115-11122. Doi: 10.1002/pros.22660.
M Alizadeh , S Alizadeh. Survey of clinical and pathological characteristics and outcomes of patients with prostate cancer. Glob J Health Sci. 2014;6:49-57. Doi:10.5539/gjhs.v6n7p49.
Z Culig, H Klocker, G Bartsch, et al. Androgen receptors in prostate cancer. Endocr-Relat Cancer. 2002:9;155-170. Doi:10.1677/erc.0.0090155.
Charles H, Clarence H. Studies on prostatic cancer I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297.
CA Heinlein, C Chang. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276-308. Doi: 10.1210/er.2002-0032.
G Corona, E Baldi, M Maggi. Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest. 2011;34:232-243. Doi:10.1007/BF03347072.
J Schleutker. Polymorphisms in androgen signaling pathway predisposing to prostate cancer. Mol Cell Endocrinol. 2012;360:25-37. Doi: 10.1016/j.mce.2011.07.007.
MHE Tan, J Li, HE Xu, et al. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36:3-23. Doi: 10.1038/aps.2014.18.
M-E Taplin, GJ Bubley, TD Shuster, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-1398. Doi:10.1056/NEJM199505253322101.
CD Chen, DS Welsbie, C Tran, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39. Doi:10.1038/nm972.
ML Zhu, N Kyprianou. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15:841-849. Doi: 10.1677/ERC-08-0084.
A Wells, J Kassis, J Solava, et al. Growth Factor-Induced Cell Motility in Tumor Invasion. Acta Oncol. 2002;41(2):124-30. Doi: 10.1080/028418602753669481.
D Sarker, AHM Reid, TA Yap, et al. Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer Clin Cancer Res. 2009;15:4799-4805. Doi: 10.1158/1078-0432.CCR-08-0125.
BY Shorning, MS Dass, MJ Smalley, et al. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int J Mol Sci. 202;21:4507. Doi:10.3390/ijms21124507.
P Thienger, MA Rubin. Prostate cancer hijacks the microenvironment. Nat Cell Biol. 2021;23:3-5. Doi: 10.1038/s41556-020-00616-3.
K-M Debatin, PH Krammer. Death receptors in chemotherapy and cancer. Oncogene. 2004;23:2950-2966. Doi: 10.1038/sj.onc.1207558.
S McKenzie, N Kyprianou. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem. 2006;97(1):18-32. Doi: 10.1002/jcb.20634.
MF McCarty. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther. 2004;3(4):349-380. Doi: 10.1177/1534735404270757.
Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon. 2013;5:792-800. Doi: 10.5812/numonthly.9430.
Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, et al. Genetic analysis of the principal genes related to prostate cancer: a review. Urol Oncol. 2013;31:1419-1429. Doi: 10.1016/j.urolonc.2012.07.011.
Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011;20:1599-1610. Doi: 10.1158/1055-9965.EPI-11-0312.
Buttyan R, Sawczuk IS, Benson MC, et al. Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate. 1987;11:327-337. Doi: 10.1002/pros.2990110405.
Qian J, Hirasawa K , Bostwick DG, et al. Loss of p53 and c-myc overrepresentation in stage T(2–3)N(1–3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol. 2002;15:35-44. Doi: 10.1038/modpathol.3880487.
Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis. 2003;8:29-37. Doi: 10.1023/a:1021692801278.
Signoretti S, Montironi R , Manola J , et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000;92:1918-1925. Doi: 10.1093/jnci/92.23.1918.
Reese DM, Small EJ, Magrane G , et al. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 2001;116:234-239. Doi: 10.1309/VXKK-YVRH-9B11-YDPT.
Lin Y, Uemura H, Fujinami K , et al. Telomerase activity in primary prostate cancer. J Urol. 1997;157:1161-1165.
Li H, Ahonen TJ, Alanen K , et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res. 2004;64:4774-4782. Doi:10.1158/0008-5472.CAN-03-3499.
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648. Doi: 10.1126/science.1117679.
Luo J, Zha S , Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 2002;62:2220-2226.
Chang B, Zheng SL, Isaacs SD, et al. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer. 2001;95:354-359. doi: 10.1002/1097-0215(20011120)95:6<354::aid-ijc1062>3.0.co;2-3.
Lamont KR, Tindall DJ. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol. 2011;25:897-907. Doi: 10.1210/me.2010-0469.
Ferraldeschi R, Welti J, Luo J, et al. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2015;34:1745-1757. Doi:10.1038/onc.2014.115.
Sun H, Lesche R , Li DM, et al. PTEN modulates cellcycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999;96:6199-204. Doi: 10.1073/pnas.96.11.6199.
Cote RJ, Shi Y , Groshen S , et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 1998;90:916-920. Doi: 10.1093/jnci/90.12.916.
Guedes LB, Almutairi F, Haffner MC, et al. Analytic, preanalytic, and clinical validation of p53 IHC for detection of TP53 missense mutation in prostate cancer. Clin Cancer Res. 2017;23:4693–4703. Doi:10.1158/1078-0432.CCR-17-0257.
Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate. 1995;26:35-39 Doi:10.1002/pros.2990260108.
Harden SV, Guo Z , Epstein JI, et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003;169:1138-1142. Doi:10.1097/01.ju.0000049627.90307.4d.
Vecchione A, Gottardo F, Gomella LG, et al. Molecular genetics of prostate cancer: clinical translational opportunities. J Exp Clin Cancer Res. 2007;26:25-37.
Ross JS, Figge HL, Bui HX, et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol. 1994;7:835-841.
Dong JT, Suzuki H , Pin SS, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996;56:4387-890.
Jaeger EB, Samant RS, Rinker-Schaeffer CW. Metastasis suppression in prostate cancer. Cancer Metastasis Rev. 2001;20:279-286. Doi: 10.1023/a:1015587411668.
